Skip to main
  1. Stocks
  2. Veracyte
  3. Forecast
VCYT

Veracyte (VCYT) Stock Forecast & Price Target

Veracyte (VCYT) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 20%
Hold 20%
Sell 10%
Strong Sell 0%

Bulls say

Veracyte is supported by a de-risked, expanding genomic diagnostics portfolio, with 3Q26 revenue of $151.8M up 15% Y/Y, adjusted EBITDA of $41.2M at a 27.2% margin, and free cash flow of $38.0M backed by $371M of cash and no debt. Its core franchises remain attractive because Decipher and Afirma still have meaningful penetration upside, while Prosigna and bladder-related tests provide additional operating leverage that could reaccelerate growth and support margin expansion beyond 2027. Although 2027 guidance for 5% revenue growth and ~22% EBITDA margin looks conservative, the company’s disciplined spending, product innovation, and strong commercial execution create multiple paths to upside as growth normalizes.

Bears say

Veracyte is facing a weakening fundamental profile because Decipher growth has decelerated, 3Q26 volume missed expectations, and management cut FY26 testing revenue guidance while resetting incremental annual Decipher growth to 12,000 to 15,000 tests from about 20,000. The company’s near-term growth is further pressured by low-risk guideline changes, DPAI-related rep distraction, and a FY27 framework that implies only mid-single-digit revenue growth and roughly 22% adjusted EBITDA margin, well below what the market expected. Although Afirma is outperforming and Prosigna, bladder, and TrueMRD add optionality, their current revenue contributions are modest, coverage is limited, and the planned ~30% urology commercial expansion should compress margins before those businesses can meaningfully offset the core slowdown.

Veracyte (VCYT) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 10% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.

Veracyte (VCYT) Analyst Forecast & Price Prediction

Get the latest Veracyte (VCYT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Veracyte (VCYT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Veracyte (VCYT) Forecast

Analysts have given Veracyte (VCYT) a Buy based on their latest research and market trends.

According to 10 analysts, Veracyte (VCYT) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Veracyte (VCYT)


Veracyte (VCYT) Analyst Forecast & Price Prediction

Get the latest Veracyte (VCYT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Veracyte (VCYT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover VCYT stock data and trends